Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival

Fast on the heels of a key success for small cell lung cancer, Roche’s Tecentriq team at Genentech has scored another frontline win for the pharma giant.